Article Text
Statistics from Altmetric.com
Ault KA, for the Future II Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 2007;369:1861–8.
Clinical impact ratings GP/FP/Primary care ★★★★★★⋆ Gynaecology ★★★★★★⋆ Public health ★★★★★★⋆
METHODS
Design:
prespecified combined analysis of 4 randomised controlled trials.
Allocation:
concealed.*
Blinding:
blinded (clinicians, participants, outcome assessors, and adjudication committee).*
Follow-up period:
mean 3 years (maximum 4 y). Follow-up started on day 1 in the intention-to-treat and susceptible populations and 1 month after the third dose of vaccine in the per protocol population.
Setting:
clinics in North America, Latin America, …
Footnotes
-
Source of funding: Merck Research Laboratories.